Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Muscle Relaxants During Electroporation Ablation (PFA) as a Potential Protective Factor Against Damage to Transverse Striated Muscle Tissue and the Heart

NCT06707532 is registered in ClinicalTrials.gov with 4th Military Clinical Hospital with Polyclinic, Poland as lead sponsor.

NCT NCT06707532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06707532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Muscle Relaxants During Electroporation Ablation (PFA) as a Potential Protective Factor Against Damage to Transverse Striated Muscle Tissue and the Heart
Lead sponsor
4th Military Clinical Hospital with Polyclinic, Poland
Phase
Not applicable
Overall status
Recruiting
Start date
August 1, 2024
Completion date
December 1, 2025
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

general anesthetic drug adverse reaction, heart arrhythmia, kidney failure, acute, muscle relaxation, myopathy; drugs, projection, succinylcholine sensitivity